SG11202107145SA - Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders - Google Patents
Compositions and methods for treating, preventing or reversing age-associated inflammation and disordersInfo
- Publication number
- SG11202107145SA SG11202107145SA SG11202107145SA SG11202107145SA SG11202107145SA SG 11202107145S A SG11202107145S A SG 11202107145SA SG 11202107145S A SG11202107145S A SG 11202107145SA SG 11202107145S A SG11202107145S A SG 11202107145SA SG 11202107145S A SG11202107145S A SG 11202107145SA
- Authority
- SG
- Singapore
- Prior art keywords
- disorders
- compositions
- treating
- preventing
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962797109P | 2019-01-25 | 2019-01-25 | |
| US201962907251P | 2019-09-27 | 2019-09-27 | |
| PCT/US2020/015043 WO2020154656A1 (en) | 2019-01-25 | 2020-01-24 | Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202107145SA true SG11202107145SA (en) | 2021-08-30 |
Family
ID=71735994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202107145SA SG11202107145SA (en) | 2019-01-25 | 2020-01-24 | Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11793814B2 (es) |
| EP (1) | EP3914604A4 (es) |
| JP (2) | JP7503558B2 (es) |
| KR (1) | KR20210137434A (es) |
| CN (1) | CN113631563A (es) |
| AU (1) | AU2020211600A1 (es) |
| BR (1) | BR112021014576A2 (es) |
| CA (1) | CA3125991A1 (es) |
| CL (1) | CL2021001951A1 (es) |
| DO (1) | DOP2021000157A (es) |
| IL (1) | IL285072A (es) |
| MX (1) | MX2021008751A (es) |
| SG (1) | SG11202107145SA (es) |
| UA (1) | UA128041C2 (es) |
| WO (1) | WO2020154656A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3927710A4 (en) * | 2019-03-08 | 2022-12-21 | University of Virginia Patent Foundation | COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF ALZHEIMER'S DISEASE |
| US20230139684A1 (en) * | 2019-11-22 | 2023-05-04 | Brown University | Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders |
| WO2022046578A1 (en) * | 2020-08-25 | 2022-03-03 | Merck Sharp & Dohme Corp. | Injectable depot compositions for the delivery of antiviral agents |
| TW202228724A (zh) * | 2020-09-23 | 2022-08-01 | 美商昂克萊亞製藥公司 | 以反轉錄酶抑制劑治療癌症之方法 |
| TW202228723A (zh) * | 2020-09-23 | 2022-08-01 | 美商崔斯波森醫療公司 | 用於治療疾病之line-1抑制劑 |
| KR20230157430A (ko) * | 2021-03-15 | 2023-11-16 | 트랜스포손 테라퓨틱스, 인코포레이티드 | Cns 및 전신 질병을 치료하기 위한 line-1 억제제 |
| CN113134003A (zh) * | 2021-05-11 | 2021-07-20 | 山东第一医科大学附属省立医院(山东省立医院) | 拉米夫定在制备治疗阿尔茨海默症药物中的应用 |
| IL309036A (en) * | 2021-06-04 | 2024-02-01 | Transposon Therapeutics Inc | LINE-1 inhibitors as cognitive enhancers |
| US20240277712A1 (en) * | 2021-06-14 | 2024-08-22 | Kyushu University, National University Corporation | Treatment and prevention of developmental disorders and mental diseases |
| WO2023019351A1 (en) * | 2021-08-16 | 2023-02-23 | University Health Network | Methods and compositions for treating alpha-synuclein-mediated neurodegeneration |
| GB202115281D0 (en) * | 2021-10-23 | 2021-12-08 | Queens Univ Of Belfast | Cardiovascular disease treament or prevention |
| WO2023105283A1 (en) * | 2021-12-08 | 2023-06-15 | Fundacio Privada Institut De Recerca De La Sida - Caixa | Nucleoside reverse transcriptase inhibitors for use in down syndrome and alzheimer`s disease therapy |
| WO2023164472A1 (en) * | 2022-02-22 | 2023-08-31 | Rome Therapeutics, Inc. | Methods of treating medical conditions using censavudine or a related compound |
| WO2023178128A1 (en) * | 2022-03-15 | 2023-09-21 | Rome Therapeutics, Inc. | Methods of treating medical conditions using islatravir or a related compound |
| CN114958852A (zh) * | 2022-06-09 | 2022-08-30 | 赛业（苏州）生物科技有限公司 | 一种Ifnar1基因敲除小鼠动物模型的构建方法及其应用 |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
| GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
| US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
| US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
| GB9315856D0 (en) | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
| US6110973A (en) | 1998-01-29 | 2000-08-29 | Sepracor | Methods for treating obesity and weight gain using optically pure (-)-bupropion |
| DE60005502T2 (de) | 1999-05-12 | 2004-06-24 | Yamasa Corp., Choshi | 4'-c-ethynyl-purin-nukleoside |
| AU2002248213A1 (en) * | 2000-12-19 | 2002-08-19 | Hospital For Special Surgery | Markers for disease susceptibility and targets for therapy |
| US20050113324A1 (en) * | 2003-01-15 | 2005-05-26 | Bondarev Igor E. | Modulation of line-1 reverse transcriptase |
| EP1613263A4 (en) | 2003-01-31 | 2007-11-28 | Pathologica Llc | MONITORING AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS |
| US7589078B2 (en) | 2003-02-19 | 2009-09-15 | Yale University | Anti-viral nucleoside analogs and methods for treating viral infections, especially HIV infections |
| WO2004090097A2 (en) | 2003-04-03 | 2004-10-21 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel human p2x7 splice variant, hbmyp2x7v |
| DK1703902T3 (da) | 2004-01-05 | 2011-02-14 | Merz Pharma Gmbh & Co Kgaa | Memantin til behandling af mild til moderat Alzheimer's sygdom |
| CA2502109C (en) | 2004-03-24 | 2010-02-23 | Yamasa Corporation | 4'-c-substituted-2-haloadenosine derivative |
| SI1999133T1 (sl) | 2006-03-29 | 2013-10-30 | Gilead Sciences, Inc. | Postopek za pripravo HIV proteaznih inhibitorjev |
| CN101627044A (zh) * | 2006-09-29 | 2010-01-13 | 艾登尼克斯药业公司 | 作为hiv抑制剂的对映体纯的膦酰吲哚 |
| WO2008054808A2 (en) * | 2006-10-31 | 2008-05-08 | Achillion Pharmaceuticals, Inc. | Elvucitabine pharmaceutical compositions |
| KR20100041798A (ko) | 2007-06-29 | 2010-04-22 | 한국화학연구원 | 신규 ｈｉｖ 역전사효소 억제제 |
| JP2010532350A (ja) | 2007-06-29 | 2010-10-07 | コレア リサーチ インスティテュート オブ ケミカル テクノロジー | 新規のｈｉｖ逆転写酵素阻害剤 |
| WO2009084655A1 (ja) | 2007-12-27 | 2009-07-09 | Oncolys Biopharma Inc. | 4'-エチニルd4Tの製造方法 |
| WO2009125841A1 (ja) | 2008-04-10 | 2009-10-15 | 浜理薬品工業株式会社 | ５－メチルウリジンを出発原料とするエチニルチミジン化合物の製造方法 |
| WO2009126293A2 (en) | 2008-04-11 | 2009-10-15 | Yale University | Potent chimeric nrti-nnrti bifunctional inhibitors of hiv-1 reverse transcriptase |
| DE102008029460A1 (de) | 2008-06-20 | 2009-12-31 | Otkrytoe Aktsionernoe Obschestvo Zavod Ekologicheskoy Tekhniki I Ekopitaniya 'diod' | Taxifolinderivate zur Prophylaxe und Behandlung von neurologischen und psychiatrischen Störungen des zentralen Nervensystems |
| JP5924479B2 (ja) | 2010-02-15 | 2016-05-25 | 日産化学工業株式会社 | β−ジヒドロフラン誘導化合物、β−ジヒドロフラン誘導化合物またはβ−テトラヒドロフラン誘導化合物の製造方法、並びにβ−グリコシド化合物の製造方法 |
| WO2012068636A1 (en) * | 2010-11-26 | 2012-05-31 | The University Of Melbourne | Methods and compositions comprising antagonists of type 1 interferon-mediated signalling for reducing a neuroinflammatory response in the central nervous system |
| ES2662373T3 (es) | 2011-01-19 | 2018-04-06 | Pathologica, Llc. | Formas de dosificación farmacéutica oral de liberación controlada que comprenden MGBG |
| TW201309706A (zh) * | 2011-07-22 | 2013-03-01 | Actelion Pharmaceuticals Ltd | 作為ｐ２ｘ７受體拮抗劑之雜環醯胺衍生物 |
| WO2013057469A1 (en) | 2011-10-20 | 2013-04-25 | Cipla Limited | Pharmaceutical antiretroviral compositions |
| CN104203244A (zh) | 2012-03-05 | 2014-12-10 | 希普拉有限公司 | 包含拉米夫定、festinnvir和奈韦拉平的抗反转录病毒药物组合物 |
| US9249171B2 (en) | 2012-05-23 | 2016-02-02 | Bristol-Myers Squibb Company | Sulfilimine and sulphoxide methods for producing festinavir |
| WO2014039696A2 (en) | 2012-09-05 | 2014-03-13 | Cold Spring Harbor Laboratory | Transposable elements, tdp-43, and neurodegenerative disorders |
| US9422605B2 (en) | 2013-03-15 | 2016-08-23 | Cold Spring Harbor Laboratory | Transposon activation during aging and neuronal decline |
| IN2013MU01749A (es) | 2013-05-15 | 2015-06-26 | Cipla Ltd | |
| US20160130260A1 (en) | 2013-06-13 | 2016-05-12 | Bristol-Myers Squibb Company | Tert-butyl sulphoxide method for producing festinavir |
| US9549942B2 (en) | 2013-07-15 | 2017-01-24 | Research & Business Foundation Sungkyunkwan University | Composition for preventing or treating degenerative brain diseases including compound downregulating expression of BACE1 proteins |
| US9993472B2 (en) * | 2014-01-28 | 2018-06-12 | Unity Biotechnology, Inc. | Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2 |
| WO2015143712A1 (en) | 2014-03-28 | 2015-10-01 | Merck Sharp & Dohme Corp. | 4'-substituted nucleoside reverse transcriptase inhibitors |
| EP2965760A1 (en) | 2014-07-09 | 2016-01-13 | Université de Montpellier | Combination of antiretroviral agents for use in the prevention or treatment of chronic inflammatory diseases |
| FR3027804A1 (fr) * | 2014-10-31 | 2016-05-06 | Centre Nat Rech Scient | Utilisation d'un inhibiteur de transcriptase inverse dans la prevention et le traitement des maladies degeneratives |
| US10059940B2 (en) | 2015-01-27 | 2018-08-28 | Minghong Zhong | Chemically ligated RNAs for CRISPR/Cas9-lgRNA complexes as antiviral therapeutic agents |
| KR102469789B1 (ko) | 2015-02-26 | 2022-11-23 | 유니버시티 오브 켄터키 리서치 파운데이션 | 망막의 퇴행을 치료하기 위한 조성물 및 방법 |
| WO2016149561A1 (en) | 2015-03-17 | 2016-09-22 | Oak Crest Institute Of Science | Subdermal implants for the sustained delivery of water-soluble drugs |
| CA2982376A1 (en) | 2015-05-28 | 2016-12-01 | Immunomedics, Inc. | T20 constructs for anti-hiv (human immunodeficiency virus) therapy and/or vaccines |
| US10363220B2 (en) | 2015-06-03 | 2019-07-30 | Triastek, Inc. | Compartmented pharmaceutical dosage forms |
| WO2017007712A1 (en) | 2015-07-04 | 2017-01-12 | Emory University | Use of trem-1 inhibitors for treatment, elimination and eradication of hiv-1 infection |
| TWI639598B (zh) | 2015-08-10 | 2018-11-01 | 美商默沙東藥廠 | 抗病毒β－胺基酸酯磷酸二醯胺化合物 |
| MX2018003212A (es) | 2015-09-23 | 2018-07-06 | Merck Sharp & Dohme | Inhibidores de transcriptasa inversa de nucleosido 4'-substituido y preparaciones de los mismos. |
| EP3353214B1 (en) * | 2015-09-25 | 2021-08-18 | Universität Duisburg-Essen | Agents inhibiting kallikrein-8 for use in the prevention or treatment of alzheimer's disease |
| WO2017059122A1 (en) | 2015-09-29 | 2017-04-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human | Methods of treating and preventing amyotrophic lateral sclerosis |
| US10745428B2 (en) | 2015-12-10 | 2020-08-18 | Idenix Pharmaceuticals Llc | Antiviral phosphodiamide prodrugs of tenofovir |
| EP3390413B1 (en) | 2015-12-15 | 2020-08-19 | Merck Sharp & Dohme Corp. | Antiviral oxime phosphoramide compounds |
| JOP20170038B1 (ar) | 2016-02-12 | 2021-08-17 | Merck Sharp & Dohme | مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه |
| CN109195633A (zh) | 2016-02-12 | 2019-01-11 | 西普拉有限公司 | 包含抗逆转录病毒药物和药代动力学增效剂的药物组合物 |
| EP3426642A4 (en) | 2016-03-09 | 2019-10-09 | Janssen BioPharma, Inc. | ACYCLIC ANTIVIRALS |
| EP3454868A4 (en) | 2016-05-12 | 2019-12-18 | Merck Sharp & Dohme Corp. | ACTIVE SUBSTANCE RELEASE SYSTEM FOR RELEASING VIRUZIDS |
| WO2017222903A1 (en) | 2016-06-20 | 2017-12-28 | Merck Sharp & Dohme Corp. | Drug delivery system for the delivery of antiviral agents |
| KR102180740B1 (ko) | 2016-08-19 | 2020-11-20 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 바이러스 감염의 예방적 또는 치유적 치료에 유용한 치료 화합물 |
| EP3503895B1 (en) | 2016-08-25 | 2021-09-15 | Merck Sharp & Dohme Corp. | Antiviral prodrugs of tenofovir |
| US10266558B2 (en) | 2016-10-07 | 2019-04-23 | Alexandre Vasilievich Ivachtchenko | Macroheterocyclic nucleoside derivatives and their analogues, production and use thereof |
| EP3532069A4 (en) | 2016-10-26 | 2020-05-13 | Merck Sharp & Dohme Corp. | ARYL-AMIDE PHOSPHODIAMIDE COMPOUNDS ANTIVIRALS |
| JOP20190130A1 (ar) | 2016-12-02 | 2019-06-02 | Merck Sharp & Dohme | مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv) |
| US20180153859A1 (en) | 2016-12-02 | 2018-06-07 | T3D Therapeutics, Inc. | Methods of treating or preventing cognitive impairment using indane acetic acid derivatives based on apoe4 genotype |
| MA47094A (fr) | 2016-12-22 | 2021-05-26 | Idenix Pharmaceuticals Llc | Promédicaments d'ester aliphatique antiviral de ténofovir |
| MX2019007262A (es) | 2016-12-22 | 2019-09-05 | Merck Sharp & Dohme | Compuestos antivirales de bencilamina fosfodiamida. |
| EA201991690A1 (ru) | 2017-01-23 | 2019-12-30 | Хелт Рисерч, Инк. | Ингибирование эндогенной обратной транскриптазы и таргетирование клеток для профилактики и терапии рака и старения |
| EP3609508A4 (en) | 2017-04-10 | 2021-02-10 | Merck Sharp & Dohme Corp. | DRUG DELIVERY SYSTEM FOR THE DELIVERY OF ANTIVIRAL AGENTS |
| UY37710A (es) | 2017-05-02 | 2018-11-30 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicación del virus de la inmunodeficiencia humana |
| EP3649249A4 (en) | 2017-07-04 | 2021-03-03 | Cavidi AB | METHOD OF EVALUATING THE SENSITIVITY OF A VIRUS TO A TREATMENT BY MEASURING ENZYMACTIVITY AND SYSTEM FOR IT |
| WO2019016679A1 (en) | 2017-07-18 | 2019-01-24 | Viiv Healthcare Company | COMBINATION THERAPY |
| AR112412A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
| AR112413A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas sólidas de un inhibidor de la cápside del vih |
| US11040975B2 (en) | 2017-12-08 | 2021-06-22 | Merck Sharp & Dohme Corp. | Carbocyclic nucleoside reverse transcriptase inhibitors |
| US20190185508A1 (en) | 2017-12-15 | 2019-06-20 | Merck Sharp & Dohme Corp. | Deuterated nucleoside reverse transcriptase inhibitors |
| WO2019133712A1 (en) | 2017-12-27 | 2019-07-04 | Schinazi Raymond F | Combined modalities for nucleosides and/or nadph oxidase (nox) inhibitors as myeloid-specific antiviral agents |
| US11839623B2 (en) | 2018-01-12 | 2023-12-12 | Board Of Regents Of The University Of Nebraska | Antiviral prodrugs and formulations thereof |
| WO2019171285A1 (en) | 2018-03-07 | 2019-09-12 | Glaxosmithkline Intellectual Property (No.2) Limited | Compounds useful in hiv therapy |
| EP3810142A4 (en) | 2018-06-20 | 2022-03-30 | Sanford Burnham Prebys Medical Discovery Institute | ANTIRETROVIRAL THERAPIES AND REVERSE TRANSCRIPTASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
| CN109893536B (zh) | 2018-07-02 | 2021-04-27 | 河南真实生物科技有限公司 | 4’-取代核苷的晶型、制备和应用 |
| JP7462969B2 (ja) | 2018-07-09 | 2024-04-08 | コデクシス， インコーポレイテッド | 操作されたデオキシリボースリン酸アルドラーゼ |
| WO2020014047A1 (en) | 2018-07-09 | 2020-01-16 | Codexis, Inc. | Engineered purine nucleoside phosphorylase variant enzymes |
| CN112996511B (zh) | 2018-07-09 | 2024-08-09 | 默沙东有限责任公司 | 4’-乙炔基核苷类似物的酶促合成 |
| TW202425967A (zh) | 2018-07-16 | 2024-07-01 | 美商基利科學股份有限公司 | 用於治療hiv之蛋白殼抑制劑 |
| WO2020018352A1 (en) | 2018-07-17 | 2020-01-23 | Merck Sharp & Dohme Corp. | Hiv drug combination for increasing barrier against resistance |
| EP3823629A4 (en) | 2018-07-19 | 2022-05-04 | Merck Sharp & Dohme Corp. | PHOSPHINAMIDE PRODRUGS OF TENOFOVIR |
| KR20210044806A (ko) | 2018-08-09 | 2021-04-23 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | Hiv 요법에 유용한 화합물 |
| EP3844164A1 (en) | 2018-08-30 | 2021-07-07 | GlaxoSmithKline Intellectual Property (No.2) Limited | Compounds useful in hiv therapy |
| JP7361766B2 (ja) | 2018-09-14 | 2023-10-16 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| US11919897B2 (en) | 2018-09-20 | 2024-03-05 | Viiv Healthcare Uk (No. 5) Limited | Inhibitors of human immunodeficiency virus replication |
| WO2020081622A1 (en) | 2018-10-16 | 2020-04-23 | Research Triangle Institute | Subcutaneous biodegradable reservoir device |
| EP3873608A1 (en) | 2018-10-31 | 2021-09-08 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
| AU2019372046B2 (en) | 2018-10-31 | 2022-05-26 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds as HPK1 inhibitors |
| EP3897660A4 (en) | 2018-12-20 | 2022-09-07 | Merck Sharp & Dohme Corp. | NEW CRYSTALLINE FORMS OF AN NRTTI COMPOUND |
| BR112021012244A2 (pt) | 2018-12-21 | 2021-09-08 | The University Of Liverpool | Produto, método de preparação de um produto, construto, e, método de tratamento |
| EP3927710A4 (en) * | 2019-03-08 | 2022-12-21 | University of Virginia Patent Foundation | COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF ALZHEIMER'S DISEASE |
| CA3149147A1 (en) * | 2019-08-23 | 2021-03-04 | Jayakrishna Ambati | Ddx17 and nlrc4 targeting for inflammatory diseases |
-
2020
- 2020-01-24 EP EP20744317.7A patent/EP3914604A4/en active Pending
- 2020-01-24 AU AU2020211600A patent/AU2020211600A1/en active Pending
- 2020-01-24 BR BR112021014576-1A patent/BR112021014576A2/pt unknown
- 2020-01-24 CA CA3125991A patent/CA3125991A1/en active Pending
- 2020-01-24 WO PCT/US2020/015043 patent/WO2020154656A1/en active Application Filing
- 2020-01-24 MX MX2021008751A patent/MX2021008751A/es unknown
- 2020-01-24 SG SG11202107145SA patent/SG11202107145SA/en unknown
- 2020-01-24 KR KR1020217023887A patent/KR20210137434A/ko unknown
- 2020-01-24 UA UAA202104068A patent/UA128041C2/uk unknown
- 2020-01-24 CN CN202080010653.1A patent/CN113631563A/zh active Pending
- 2020-01-24 JP JP2021543271A patent/JP7503558B2/ja active Active
- 2020-07-21 US US16/934,826 patent/US11793814B2/en active Active
-
2021
- 2021-07-22 IL IL285072A patent/IL285072A/en unknown
- 2021-07-22 DO DO2021000157A patent/DOP2021000157A/es unknown
- 2021-07-23 CL CL2021001951A patent/CL2021001951A1/es unknown
-
2023
- 2023-09-19 US US18/470,182 patent/US20240197745A1/en active Pending
-
2024
- 2024-06-10 JP JP2024093541A patent/JP2024116287A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CL2021001951A1 (es) | 2022-04-08 |
| EP3914604A1 (en) | 2021-12-01 |
| BR112021014576A2 (pt) | 2021-10-05 |
| MX2021008751A (es) | 2021-11-12 |
| JP2022521454A (ja) | 2022-04-08 |
| US20210106586A1 (en) | 2021-04-15 |
| US11793814B2 (en) | 2023-10-24 |
| IL285072A (en) | 2021-09-30 |
| DOP2021000157A (es) | 2021-11-21 |
| US20240197745A1 (en) | 2024-06-20 |
| CN113631563A (zh) | 2021-11-09 |
| CA3125991A1 (en) | 2020-07-30 |
| JP2024116287A (ja) | 2024-08-27 |
| JP7503558B2 (ja) | 2024-06-20 |
| EP3914604A4 (en) | 2022-10-19 |
| UA128041C2 (uk) | 2024-03-20 |
| AU2020211600A1 (en) | 2021-07-22 |
| KR20210137434A (ko) | 2021-11-17 |
| WO2020154656A1 (en) | 2020-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285072A (en) | Preparations and methods for the treatment, prevention or reversal of age-related inflammations and disorders | |
| EP3630058A4 (en) | COMPOSITIONS AND PROCEDURES TO PREVENT, DECELERATE AND REVERSE SKIN AGING | |
| EP3612215A4 (en) | COMPOSITIONS AND METHODS OF TREATMENT OF Pneumonia | |
| AU2018297285A1 (en) | Compositions and methods for treating or preventing endocrine FGF-linked diseases | |
| EP3858353A4 (en) | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING NITM AND ASSOCIATED PHARMACEUTICAL USE | |
| EP3609525A4 (en) | COMPOSITIONS AND METHODS OF TREATMENT OR PREVENTION OF INTESTINAL PERMEABILITY DISORDERS | |
| IL282375A (en) | For the delay and treatment of synucleopathy, tauopathy and other diseases 2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE | |
| EP3829299A4 (en) | BISMUTH THIOL COMPOSITIONS AND METHODS OF TREATMENT OF WOUNDS | |
| EP3801477A4 (en) | METHODS AND COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF TISSUE CALCIFICATION | |
| EP3801478A4 (en) | METHODS AND COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF CALCIPHYLAXIS | |
| EP3931336A4 (en) | COMPOSITIONS AND METHODS FOR TREATMENT OF LAMINOPATHIES | |
| EP3847283A4 (en) | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HER INDUCED CANCERS | |
| EP3870210A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF FIBROSIS | |
| GB202018908D0 (en) | Compositions and methods for treating and preventing muscular disorders and dystrophies, steroid side effects, and inflammation | |
| EP3893785A4 (en) | COMPOSITIONS AND METHODS FOR TREATMENT OF WOUNDS | |
| EP3760215A4 (en) | COMPOSITION INTENDED TO PREVENT, ALLEVIATE OR TREAT CACHEXIA AND MUSCLE WASTING | |
| GB202001422D0 (en) | Compositions and methods for preventing or treating nephrolithiasis | |
| EP3965799A4 (en) | SYNERGIC COMPOSITIONS AND METHODS OF TREATING INFECTIONS | |
| EP3814372A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PAIN, INFLAMMATION, INFECTION, MALARIA AND SEPSIS | |
| EP3790565A4 (en) | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING GUT BARRIER DYSFUNCTION | |
| AU2018301500A1 (en) | Methods and compositions for treating inflammation | |
| EP3638287A4 (en) | METHODS AND COMPOSITIONS FOR TREATING MICROBIAL INFLAMMATION | |
| EP3893877A4 (en) | COMPOSITIONS, DEVICES AND METHODS FOR TREATMENT OR PREVENTION OF HEADACHE | |
| HUE066936T2 (hu) | Rifabutin kezelési eljárások, felhasználások és készítmények | |
| EP3946302A4 (en) | METHODS AND COMPOSITIONS FOR PAIN MANAGEMENT |